Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”) is pleased to announce the Health Canada approval and launch of the first of its ‘420 Therapeutics’ brand of Cannabis wellness products: Hemp Oil Gel Capsules. Made from purified organic hemp seed oil, the Hemp Oil Gel Capsules are an easy and convenient way to enjoy the health benefits of hemp oil.

Each Hemp Oil Gel Capsule contains 50 milligrams of purified hemp seed oil extracted from cannabis sativa and suspended in high grade coconut oil. These ingredients have been linked to the following health benefits:


  • Omega 3 Fatty Acids (alpha linolenic acid) and Omega 6 Fatty Acids (linolenic acid) are antioxidants that help protect the body’s cells and shields it from the oxidative damage caused by free radicals.
  • Coconut oil contains Lauric acid that is proven to be effective at killing bacteria, fungi and certain viruses.
  • Capric acid and medium triglycerides help increase the body’s energy expenditure for weight control and also aid in building muscle.


Figure 1: Hemp Oil Capsules

Cannot view this image of the Hemp Oil Capsules?
Please visit [http://orders.newsfilecorp.com/files/5789/35380_a1529501756578_36.jpg] to view this image

Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “We are excited to announce the launch of Hemp Oil Gel Capsules, which are the first in our innovative line of 420 Therapeutics products. We intend to release additional exciting formulations that combine natural, hemp-based cannabidiol with a range of healthy ingredients. This is only the first step in realizing Canntab’s goal of becoming a leading provider of cannabis oral dosage formulations.”

Mr. Richard Goldstein, Chief Financial Officer of Canntab, added, “All of our 420 Therapeutics products will use state of the art tamper-proof blister packaging, which allows us to avoid the leakage that often occurs when capsules are kept in large bottles, since the capsules kept in bottles frequently bounce off one another and become damaged. Our packaging keeps the underlying product intact, and provides for discretionary and safe consumption of one capsule at a time.”

About 420 Therapeutics

420 Therapeutics Inc. (“420 Therapeutics”) is a wholly-owned subsidiary of Canntab that was created to answer a growing desire for adult use cannabis products that are of high quality, but without the negative effects associated with smoking marijuana. Our research and development protocols ensure that each 420 Therapeutics product offers a uniform dosage of high quality cannabis extract, which we verify through extensive testing. “420 Therapeutics” is also a trademark of Canntab.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
info@canntab.ca

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

The information and statements in this news release contain certain forward-looking information relating to the implementation, timing, and roll out of the future 420 Therapeutics products, including ingredients, cannabidiol content, and possible health benefits. This news release also contains certain forward-looking statements relating to future business objectives. This forward-looking information is subject to certain risks and uncertainties and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward-looking information. Canntab’s forward-looking information is expressly qualified in its entirety by this cautionary statement. Except as required by law, Canntab undertakes no obligation to publicly update or revise any forward-looking information.

Click here to connect with Canntab Therapeutics Limited (CSE:PILL) for an Investor Presentation.

Source: www.newsfilecorp.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less